A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
This is a phase 1/2 multicenter, first-in-human study of IBI129. It includes a phase 1 dose
escalation and expansion section to identify MTD/RP2D of IBI129, plan to enroll 22~180
subjects, and a phase 2 to explore efficacy, safety and tolerability of IBI129 at RP2D in
specified types of solid tumor. Approximately 182 evaluable subjects will be enrolled for
phase 2